Direct-acting antiviral agents for HCV infection affecting people who inject drugs - Nature Reviews Gastroenterology & Hepatology

Clicks: 209
ID: 268932
2017
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #47 of 101 articles by views in nature reviews gastroenterology & hepatology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Direct-acting antiviral agents (DAAs) are highly effective treatments for HCV, but are not always accessible to people who inject drugs (PWID). Here, Grebely and colleagues outline the epidemiology of HCV in PWID, discuss current data on DAA outcomes in this population and highlight steps required to broaden access to HCV therapy with the eventual goal of HCV elimination.
Reference Key
jason2017naturedirect-acting Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Grebely, Jason;Hajarizadeh, Behzad;Dore, Gregory J.;Grebely, Jason;Hajarizadeh, Behzad;Dore, Gregory J.;
Journal nature reviews gastroenterology & hepatology
Year 2017
DOI
doi:10.1038/nrgastro.2017.106
URL
http://dx.doi.org/10.1038/nrgastro.2017.106
Keywords
health policy hepatitis c hepatitis c virus drug therapy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.